OOIR: Observatory of International Research

Papers

(The H4-Index of Journal for Immunotherapy of Cancer is 66. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
73 Characterization of tumor-infiltrating T-cell repertoire in human cancers	238
217 Cytotoxicity of nicotinamide enhanced natural killer cells GDA201 is based on metabolic modulation as demonstrated by artificial intelligence assisted analysis of NK cell transcriptome and metabol	195
38 Spatial immune profiling of human glioblastoma tissue reveals the presence of aggregated lymphoid niches in the tumor microenvironment	194
Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models	159
Response to "NLRC5germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng	152
Correction: Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design	150
Correction: Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy	139
Correction: Treg-selective IL-2 starvation synergizes with CD40 activation to sustain durable responses in lymphoma models	138
Correction: A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer	137
Correction: PP4 inhibition sensitizes ovarian cancer to NK cell-mediated cytotoxicity via STAT1 activation and inflammatory signaling	137
Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells	132
24 Nivolumab serum concentration in metastatic melanoma patients could be related to anti-tumor activity gene and outcome	128
Oncolytic adenovirus serotype 35 mediated tumor growth suppression via efficient activation of antitumor immunity	123
Hybrid epithelial-mesenchymal status of lung cancer dictates metastatic success through differential interaction with NK cells	120
TIPE2deletion improves the therapeutic potential of adoptively transferred NK cells	120
Correction: Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer	119
Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunothera	117
Intratumoral microbiota predicts the response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer	112
T-cell tolerant fraction as a predictor of immune-related adverse events	112
Author response to comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer	110
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors	109
GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma	105
Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach	105
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap	104
Correction: influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors	101

Correction: Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockade	99
Inhibition of PNCK inflames tumor microenvironment and sensitizes head and neck squamous cell carcinoma to immune checkpoint inhibitors	98
Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders	94
B7-H3 CAR-T cell therapy combined with irradiation is effective in targeting bulk and radiation-resistant chordoma cancer cells	93
HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype	93
Cbl-b inhibitor NX-1607 activates MAPK/ERK signaling pathway and enhances T-cell activation	92
Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers	92
Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis	91
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study	89
Is immunotherapy safe and effective in patients with VEXAS syndrome?	89
Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy	88
Pancreatic cancer cell-intrinsic transglutaminase-2 promotes T cell suppression through microtubule-dependent secretion of immunosuppressive cytokines	88
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy	86
Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression	84
Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study	82
Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival	81
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision	80
Commentary on oncolytic viruses: past, present, and future	78
Constructing a pancancer ubiquitination regulatory network to determine tumor characteristics, immunotherapy response, and prognosis	78
Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade	77
Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy	76
Evaluation of immune checkpoint inhibitor efficacy for solid tumors withCD274(PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwide	76
Lactylation-driven TNFR2 expression in regulatory T cells promotes the progression of malignant pleural effusion	75
Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma	75
Biomarkers for response to TIL therapy: a comprehensive review	75
Single-cell analysis reveals clonally expanded tumor-associated CD57⁺CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade	74
Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study	74
iRECIST and atypical patterns of response to immuno-oncology drugs	74
Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression	73
Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases	72
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses	70
Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer	70
Macrophage-inherited exosome excise tumor immunosuppression to expedite immune-activated ferroptosis	70
Zelig Eshhar (1941–2025): a tribute for a life for immunotherapy	69
Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments	69
370 Time course of treatment-related adverse events (TRAEs) during dostarlimab therapy in the GARNET trial	68
389 Phase II of CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy	68
17 Predictive soluble biomarkers of immune response to checkpoint blockade in non-small cell lung cancer (NSCLC) patients	68
Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies	67
77 Prevalence of secondary immunotherapeutic targets in the absence of established immune biomarkers in solid tumors	67
Irreversible electroporation synergizes with oncolytic virus enhances the infiltration of cytotoxic T lymphocytes in the tumor immune microenvironment: a leap from focal therapy to immunotherapy for p	66